Ledipasvir-sofosbuvir plus ribavirin for patients with genotype 1 hepatitis C virus previously treated in clinical trials of sofosbuvir regimens | HCV Guidance

HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C

Ledipasvir-sofosbuvir plus ribavirin for patients with genotype 1 hepatitis C virus previously treated in clinical trials of sofosbuvir regimens

Wyles DL, Pockros P, Morelli G, Younes Z, Svarovskaia ES, Yang JC, et al. Ledipasvir-sofosbuvir plus ribavirin for patients with genotype 1 hepatitis C virus previously treated in clinical trials of sofosbuvir regimens. Hepatology. 2015;61(6):1793-1797.

Publication Type:

Journal Article

Authors:

D L Wyles; Pockros, P.; Morelli, G.; Younes, Z.; E. S. Svarovskaia; Yang, J.C.; Pang, P.S.; Zhu, Y.; J G McHutchison; Flamm, S.; E J Lawitz

Source:

Hepatology, Volume 61, Issue 6, p.1793-1797 (2015)

Keywords:

Bipolar Disorder, California, Chicago, Cities, clinical trial, Clinical Trials, Diarrhea, Fatigue, Florida, Genotype, genotype 1, HCV, Headache, Health, hepatitis, Hepatitis C, hepatitis C virus, interferon, Liver, Medicine, monotherapy, Patients, pegylated, pegylated interferon, Retreatment, Ribavirin, Safety, sofosbuvir, SVR, Texas, therapy, treatment, United States, Universities

Cited On:

External Third-party Web Link:

http://www.ncbi.nlm.nih.gov/pubmed/25846014

Export Citation:

RIS Format

Top